Gates Commits $89m To Novavax After Maternal RSV Vaccine Success

Now that Novavax Inc.'s respiratory syncytial virus (RSV) vaccine has succeeded in a Phase II clinical trial in pregnant women, the Bill & Melinda Gates Foundation has committed up to $89m to help the company fund a massive Phase III trial that will include sites in developing countries.